Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605213 | 0.84 | KCNA5 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3955653 | 0.81 | CTSL (0.36) | STSRORCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3955650 | 0.81 | CTSL (0.36) | STSRORCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6605969 | 0.79 | SLC6A2 (0.37) | STSRORCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6605965 | 0.79 | SLC6A2 (0.37) | STSRORCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6610805 | 0.74 | CD274 (0.33) | SLC6A2SLC6A4 | |
| SCHEMBL6589700 | 0.71 | SIGMAR1 (0.35) | SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL7562353 | 0.71 | CYP3A4 (0.38) | CA1CA2 | |
| SCHEMBL6214730 | 0.70 | EPHX1 (0.40) | — | |
| SCHEMBL6590820 | 0.70 | EPHX1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796677-A4 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1796677-A2 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029209-A2 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |